



## **Senior Management HR Announcement**

October 14th, 2016 Baar, Switzerland

**Amicus S.A.** announced today that Ivan Pertot had joined the Company as **Regional BD Director, Added-Value Brands**, effective October 1<sup>st</sup>, 2016. Ivan will report directly to Predrag Lukic, Regional Director, Non-EU Countries and GM Serbia. He will have a dotted-line reporting relationship to Stuart Swanson, Head of Corporate Development, and Jean-Michel Lespinasse, CEO.

Ivan joins Amicus as an accomplished professional executive, with over 11 years' experience working for, and with, research-based, multinational pharmaceutical and healthcare companies. With a background in sales, regulatory and business development and leadership of teams, Ivan is well-prepared to lead Amicus' efforts to develop a stable of its own products to provide balance and complement Amicus' dominant focus, which is representing research-based healthcare companies.

After graduating from the Faculty of Pharmacy at Belgrade University, Ivan launched his career in the pharmaceutical industry as a medical representative at Schering-Plough. He then moved into Regulatory Affairs and Pharmacovigilance/Safety at Schering-Plough and then moved on to PharmaSwiss S.A. in 2007, where he was rapidly promoted to Director Regulatory Affairs Serbia in 2009. Promoted again in 2013, Ivan became Regional Regulatory Director at PharmaSwiss / Valeant for the (Non-EU) Balkans, managing a team of 14 Regulatory and safety professionals in five countries, responsible for registering and maintaining over 500 product registrations – pharmaceuticals, medical devices, food supplements and biocides.

Amicus COO and Regional Director Non-EU, Predrag Lukic, warmly greeted Ivan to Amicus: "I have worked with Ivan for most of his and my career, and all I can say is that I cannot think of a better person to lead our value-added brand effort," opined Lukic. I wish him every success, I congratulate him on this promotion, and I look forward to working with Ivan to bring new products to our West Balkan region swiftly and effectively."

Amicus' Head of Corporate Development and Board member Stuart Swanson also expressed deep satisfaction with Ivan's arrival at Amicus: "I am excited to work with Ivan again," Swanson said. He brings a marvelous talent set to Amicus. Possessed of an enquiring and creative mind, high energy, and infectious enthusiasm, Ivan will be a great driver for some of our most strategic projects. He is smart and has a wealth of contacts. Further, the fact is that Serbia is not only our largest market by population, but also in a real sense represents the primary test market for first launch of our own products. Having Ivan leading our BD efforts on Amicus own brands in the first wave and critical non-EU region (and assisting corporate-wide BD on Added-Value Brands), will enhance our capabilities," Swanson enthused. "I welcome Ivan to the Amicus family."

Petr Nemec, Co-Founder, Strategist and Board Member noted that "bringing Ivan into Amicus is a significant step for the company. Not only have we recruited a senior executive team that is committed, and experienced, in BD in a way that I think is quite unusual for companies like our own – with Ivan, we now are adding further depth and dimension to an excellent BD department. We want to create unique, value-added and sometimes counter-intuitive brands that complement and support our core MNC representation business. With Ivan on our side, managing very complex regulatory, manufacturing, sourcing and relationship issues – and also working with our country teams to prepare them for new launches -- I am doubly sure we will succeed."

## About Amicus S.A.

Headquartered in Baar, Switzerland, Amicus subsidiaries operate in the Western Balkan countries of Albania, Bosnia-Herzegovina, Croatia, Kosovo, Macedonia, Montenegro, Serbia and Slovenia and the Baltic countries of Estonia, Latvia, Lithuania. Set up in 2014, Amicus specializes in representing research-based pharmaceutical and branded self-care brands across the West Balkans and Baltics.

For more info about Amicus, please visit: www.amicuspharma.eu